Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza a (H1N1) infection

Japanese Journal of Infectious Diseases

Volumn 66, Issue 5, 2013, Pages 425-427

  Kang, Seung Ji ^a   Park, Kyung Hwa ^a   Kee, Seung Jung ^a   Shin, Jong Hee ^a   Jung, Sook In ^a   Kwon, Yong Soo ^a   Jang, Hee Chang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Combination; Drug therapy; H1N1 subtype; Influenza A virus; Oseltamivir

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIBAVIRIN; VIRUS SIALIDASE;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS SHEDDING;

ADOLESCENT; ADULT; AGED; AMANTADINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; RESPIRATORY DISTRESS SYNDROME, ADULT; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884404800     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.66.425     Document Type: Article

References (23)

1. To, K.K., Hung, I.F., Li, I.W., et al. (2010): Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis., 50, 850-859.
2. Anton, A., Lopez-Iglesias, A.A., Tortola, T., et al. (2010): Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn. Microbiol. Infect. Dis., 68, 214-219.
3. Hong, S.D., Park, S.H., Kang, S.J., et al. (2011): First fatal oseltamivir-resistant 2009 pandemic influenza A (H1N1) case in an adult in Korea. Chonnam Med. J., 47, 127-129.
4. World Health Organization (WHO) (2010): WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and Other Influenza Viruses. Online at .
5. Smee, D.F., Hurst, B.L., Wong, M.H., et al. (2009): Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother., 53, 2120-2128.
6. Nguyen, J.T., Hoopes, J.D., Le, M.H., et al. (2010): Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PloS One, 5(2), e9332.
7. Nguyen, J.T., Hoopes, J.D., Smee, D.F., et al. (2009): Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob. Agents Chemother., 53, 4115-4126.
8. Ilyushina, N.A., Bovin, N.V., Webster, R.G., et al. (2006): Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res., 70, 121-131.
9. Hoopes, J.D., Driebe, E.M., Kelley, E., et al. (2011): Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PloS One, 6(12), e29778.
10. Glezen, W.P. (2008): Clinical practice. Prevention and treatment of seasonal influenza. N. Engl. J. Med., 359, 2579-2585.
11. Kim, W.Y., Young Suh, G., Huh, J.W., et al. (2011): Triplecombination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob. Agents Chemother., 55, 5703-5709.
12. World Health Organization (WHO) (2009): WHO Information for Laboratory Diagnosis of Pandemic (H1N1) 2009 Virus in Humans-Revised. Updated on November 2009. Online at .
13. Hwang, Y., Kim, K. and Lee, M. (2010): Evaluation of the efficacies of rapid antigen test, multiplex PCR, and real-time PCR for the detection of a novel influenza A (H1N1) virus. Korean J. Lab. Med., 30, 147-152.
14. Ling, L.M., Chow, A.L., Lye, D.C., et al. (2010): Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin. Infect. Dis., 50, 963-969.
15. Giannella, M., Alonso, M., Garcia de Viedma, D., et al. (2011): Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin. Microbiol. Infect., 17, 1160-1165.
16. Nakamura, K., Schwartz, B.S., Lindegardh, N., et al. (2010): Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin. Infect. Dis., 50, e47-49.
17. Dutkowski, R., Smith, J.R. and Davies, B.E. (2010): Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int. J. Antimicrob. Agents, 35, 461-467.
18. Rello, J., Rodrfá guez, A., Ibanãez, P., et al. (2009): Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit. Care, 13, R148.
19. Beigel, J. and Bray, M. (2008): Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res., 78, 91-102.
20. Watcharananan, S.P., Suwatanapongched, T., Wacharawanichkul, P., et al. (2010): Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure. Transpl. Infect. Dis., 12, 127-131.
21. Tekgunduz, E., Yuksel, M.K., Erbay, C., et al. (2010): Pandemic 2009 H1N1 influenza in patients with hematopoietic stem cell transplantation and hematologic malignancy: single center experience. Oncology, 79, 409-414.
22. Kumar, A., Zarychanski, R., Pinto, R., et al. (2009): Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA, 302, 1872-1879.
23. Dominguez-Cherit, G., Lapinsky, S.E., Macias, A.E., et al. (2009): Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA, 302, 1880-1887.